Tirilazad Mesylate Increases Dopaminergic Neuronal Survival in thein OculoGrafting Model

Grafting of fetal ventral mesencephalon in Parkinson's disease has been extensively studied. A crucial draw back of this technique is the low survival rate of the dopaminergic neurons. It has been documented that only 5-20% of the grafted neurons survive, and to enhance graft efficacy to a satisfying level, increased cell survival is of utmost desire. In this study we have used the antioxidant tiriliazad mesylate (U-74006F) to study the effect on the survival of dopaminergic neurons after grafting. The in oculo grafting model was used and ventral mesencephalon was dissected from E14-E15 rat fetuses in Hanks' balanced salt solution (HBSS), in Dulbecco's modified Eagle medium (DMEM), or in 0.3, 3.0, or 30 microM U-74006F diluted in DMEM. The tissue was then inserted into the anterior chamber of the eye. Some of the transplants were further treated with intraocular injections of 3 or 30 microM U-74006F (5 microliters) weekly for 2 weeks. Quantification of tyrosine hydroxylase (TH)-immunoreactive profiles revealed that in transplants treated with U-74006F at dissection only, no change in the number of TH-positive neurons was found. Pretreatment of 0.3 microM U-74006F during dissection combined with intraocular injections of U-74006F after grafting, on the other hand, resulted in a dose-dependent enhancement of survival of TH-positive neurons. Dissection in, and intraocular treatment with, 3 microM U-74006F resulted in a significantly enhanced survival of TH-positive neurons whereas using U-74006F at a concentration of 30 microM did not change the cell survival compared to solely DMEM-treated grafts. Thus, 30 microM was interpreted to be an overdose. Comparing cell survival when dissected in DMEM with that dissected in HBSS showed that DMEM was clearly superior. Nerve fiber formation was most pronounced in grafts treated with 3 microM U-74006F. In conclusion, survival of TH-positive neurons is enhanced by U-74006F, which is readily available for clinical use and thus could be employed to enhance graft survival when transplanting patients suffering from Parkinson's disease.

[1]  L. Symon,et al.  Advances and Technical Standards in Neurosurgery , 1999, Advances and Technical Standards in Neurosurgery.

[2]  C. Olanow,et al.  An introduction to the free radical hypothesis in Parkinson's disease , 1992, Annals of neurology.

[3]  J. Fawcett,et al.  GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. , 1996, Neuroreport.

[4]  I. Strömberg,et al.  Effects of Glial Cell Line-Derived Neurotrophic Factor on Developing and Mature Ventral Mesencephalic Grafts in Oculo , 1995, Experimental Neurology.

[5]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[6]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[7]  Rhonda,et al.  Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  G. Rose,et al.  Monoamine release from dopamine-depleted rat caudate nucleus reinnervated by substantia nigra transplants: An in vivo electrochemical study , 1985, Brain Research.

[9]  J. Powell,et al.  Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[10]  J. Tepper,et al.  Electrophysiological characteristics of cells within mesencephalon suspension grafts , 1991, Neuroscience.

[11]  B. J. Hopper,et al.  FETAL DOPAMINE-RICH MESENCEPHALIC GRAFTS IN PARKINSON'S DISEASE , 1988, The Lancet.

[12]  L. Olson,et al.  Fibroblast growth factors enhance dopamine fiber formation from nigral grafts. , 1993, Brain research. Developmental brain research.

[13]  L. Olson,et al.  Intraocular Transplantation in Rodents: A Detailed Account of the Procedure and Examples of its Use in Neurobiology with Special Reference to Brain Tissue Grafting , 1983 .

[14]  L. Olson,et al.  Substantia nigra transplants into denervated striatum of the rat: Ultrastructure of graft and host interconnections , 1985, The Journal of comparative neurology.

[15]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Jaeger.  Cytoarchitectonics of substantia nigra grafts: A light and electron microscopic study of immunocytochemically identified dopaminergic neurons and fibrous astrocytes , 1985, The Journal of comparative neurology.

[17]  J. Tepper,et al.  Postnatal changes in the distribution and morphology of rat substantia nigra dopaminergic neurons , 1994, Neuroscience.

[18]  P. Brundin,et al.  Lazaroids improve the survival of grafted rat embryonic dopamine neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  F. Gage,et al.  In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis , 1986, Brain Research.

[20]  L. Olson,et al.  Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation , 1986, Neuroscience Letters.

[21]  E. Hall,et al.  Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. , 1988, Journal of neurosurgery.

[22]  C. Gerfen,et al.  The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  E. Hall,et al.  Effects of the 21-aminosteroid U74006F on experimental head injury in mice. , 1988, Journal of neurosurgery.

[24]  L. Olson,et al.  Nerve growth factors in the rat iris , 1980, Nature.

[25]  G. Owens,et al.  Programmed Cell Death in Developing Grafts of Fetal Substantia Nigra , 1994, Experimental Neurology.

[26]  E. Hall,et al.  Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. , 1994, Advances in pharmacology.

[27]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[28]  M. Thomas,et al.  The novel 21-aminosteroid U74006F attenuates cerebral edema and improves survival after brain injury in the rat. , 1992, Journal of neurotrauma.

[29]  N. Weiner,et al.  Function of intraventricular human mesencephalic xenografts in immunosuppressed rats: An electrophysiological and neurochemical analysis , 1991, Experimental Neurology.

[30]  I. Date,et al.  MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF) , 1990, Brain Research.

[31]  C. Spenger,et al.  Comparison of the Effects of the Neurotrophins on the Morphological Structure of Dopaminergic Neurons in Cultures of Rat Substantia Nigra , 1995, The European journal of neuroscience.

[32]  A. Bjo¨rklund,et al.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants , 1979, Brain Research.

[33]  E. Hall,et al.  Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. , 1989, Free radical biology & medicine.

[34]  S. Rehncrona.  A critical review of the current status and possible developments in brain transplantation. , 1997, Advances and technical standards in neurosurgery.

[35]  G. Arbuthnott,et al.  Electrophysiological properties of single units in dopamine-rich mesencephalic transplants in rat brain , 1985, Neuroscience Letters.

[36]  L. Olson,et al.  Parasympathetic neurotrophic activity in the rat iris: Determination after different denervations , 1985, Neuroscience.

[37]  F. Hefti,et al.  The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth FACTOR-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture , 1993, Neuroscience.

[38]  K. Unsicker,et al.  Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  E. Clarkson,et al.  GDNF reduces apoptosis in dopaminergic neurons in vitro , 1995, Neuroreport.

[40]  L. Pitts,et al.  Effect of U74006F on neurologic function and brain edema after fluid percussion injury in rats. , 1993, Journal of neurotrauma.

[41]  I. Strömberg,et al.  The age of striatum determines the pattern and extent of dopaminergic innervation: a nigrostriatal double graft study. , 1997, Cell transplantation.

[42]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[43]  W. Mathews,et al.  The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. , 1996, The Journal of pharmacology and experimental therapeutics.

[44]  L. Olson,et al.  Glial Cell Line-Derived Neurotrophic Factor Is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in Vivo , 1993, Experimental Neurology.

[45]  L. Hertz,et al.  Advances in Cellular Neurobiology , 1983 .

[46]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[47]  P. Brundin,et al.  Lazaroids improve the survival of cultured rat embryonic mesencephalic neurones. , 1994, Neuroreport.

[48]  H. Phillips,et al.  Neurotrophic‐4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures , 1994 .

[49]  L. Studer,et al.  Effect of BDNF on Dopaminergic, Serotonergic, and GABAergic Neurons in Cultures of Human Fetal Ventral Mesencephalon , 1995, Experimental Neurology.

[50]  G. D. Johnson,et al.  A simple method of reducing the fading of immunofluorescence during microscopy. , 1981, Journal of immunological methods.

[51]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[52]  M. Abercrombie.  Estimation of nuclear population from microtome sections , 1946, The Anatomical record.

[53]  E. Hall,et al.  Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. , 1989, Free radical biology & medicine.

[54]  B J Hoffer,et al.  Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. , 1979, Science.

[55]  P. Stieg,et al.  Behavioral and electrophysiological correlates of human mesencephalic dopaminergic xenograft function in the rat striatum , 1990, Brain Research Bulletin.

[56]  C. Gerfen,et al.  The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[57]  F. Hefti,et al.  Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  B. Coull,et al.  Lazaroids. CNS pharmacology and current research. , 1995, Drugs.

[59]  M. Trulson,et al.  Dopamine neuron transplants: electrophysiological unit activity of intrastriatal nigral grafts in freely moving cats. , 1987, Life sciences.